Note: Ingredients listed on restricted chemical lists
EC/CAS
232-674-9/9004-34-6
Name of the chemical
cellulose
Concentration
10-30%
General Information
Revision date
2016-08-26
Product name
Viibryd
Product Synonyms
Vilazodone - EMD 68843, SB 659746, SB 659746A, 5-{4-[4-(5-Cyano-3-indolyl)- butyl] 1-piperazinyl} -benzofuran-2 carbozamide hydrochloride
Chemical name
Vilazodone Hydrochloride
1.2.1 Relevant identified uses
Pharmaceutical product PREPARED BY Environmental Health and Safety Department
Emergency telephone
1-800-424-9300, +1-703-527-3887
Icons in SDS
Company Information
company name
EUROPE
e-mail address of the competent person responsible for the Safety Data Sheet
SDS@allergan.com
GHS Information
Signal word
Attention
Section 2
SECTION 2: Hazards identification
Directive 1999/45/EC: Vilazodone ppm mg/m3
Signal word
Attention US HAZARD OVERVIEW: Possible developmental hazard - May adversely affect the developing fetus (based on effects in animals at moderate to high doses). Overexposure may cause gastrointestinal (nausea, diarrhea, dry mouth, vomiting), psychiatric (insomnia, abnormal dreams, anxiety, nightmares), and nervous system (headache, dizziness, somnolence, tremor) effects. If tablets are crushed/broken: Dust clouds are sensitive to electrostatic ignition. Ignition of dust clouds produces a strong explosion. CLASSIFICATION OF THE SUBSTANCE OR MIXTURE: Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information Not Required
Hazard statements
Not Required CLP/GHS PERCAUTIONARY STATEMENTS: Not Required
2.3 Other hazards
In the dose range most commonly tested of between 10 and 100 mg/day by oral administration, the most frequently reported adverse effects included gastrointestinal (nausea, diarrhea, dry mouth, vomiting), psychiatric (insomnia, abnormal dreams, anxiety, nightmares), and nervous system (headache, dizziness, somnolence, tremor).
Medical Conditions Generally Aggravated by Exposure
Not tested CARCINOGENICITY
2.1 Classification of the substance or mixture
the most frequently reported adverse effects included gastrointestinal (nausea, diarrhea, dry mouth, vomiting), psychiatric (insomnia, abnormal dreams, anxiety, nightmares), and nervous system (headache, dizziness, somnolence, tremor). MEDICAL CONDITIONS GENERALLY AGGRAVATED BY EXPOSURE: Not tested.
